Published in J Int Neuropsychol Soc on November 24, 2010
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain (2014) 1.70
The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord (2014) 1.17
Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol (2014) 0.95
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. Neurology (2012) 0.90
Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. Parkinsonism Relat Disord (2014) 0.88
Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease. FEBS Lett (2015) 0.78
Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation. Mov Disord (2013) 0.77
Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease. Mov Disord Clin Pract (2016) 0.75
Brain Connectivity Changes in Autosomal Recessive Parkinson Disease: A Model for the Sporadic Form. PLoS One (2016) 0.75
Associations among Cognitive Functions, Plasma DNA, and White Matter Integrity in Patients with Early-Onset Parkinson's Disease. Front Neurosci (2017) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
An inventory for measuring depression. Arch Gen Psychiatry (1961) 84.61
Longitudinal data analysis for discrete and continuous outcomes. Biometrics (1986) 60.93
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology (2005) 3.29
Parkin disease: a phenotypic study of a large case series. Brain (2003) 2.41
Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A (2005) 2.27
Accuracy of family history data on Parkinson's disease. Neurology (2003) 2.15
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method. Arch Neurol (2008) 1.81
A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology (2008) 1.74
Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology (2003) 1.70
Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain (2003) 1.68
Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology (2008) 1.60
Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol (2005) 1.60
Cognitive impairments associated with early Parkinson's disease. Neurology (1989) 1.59
Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol (2006) 1.47
Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease. J Neurol Neurosurg Psychiatry (1999) 1.47
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol (2010) 1.38
Familial aggregation of early- and late-onset Parkinson's disease. Ann Neurol (2003) 1.35
The California Verbal Learning Test--second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms. Arch Clin Neuropsychol (2006) 1.31
Cognitive decline in Parkinson's disease: a prospective longitudinal study. J Int Neuropsychol Soc (2009) 1.31
Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol (2006) 1.26
Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene. Mov Disord (2007) 1.07
Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology (2008) 1.03
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol (2010) 1.03
Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet (2007) 1.02
Non-motor behavioural impairments in parkin-deficient mice. Eur J Neurosci (2007) 1.01
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years. Mov Disord (2005) 0.94
The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet (2001) 0.93
Conventional intelligence measurements and neuropsychological concepts of adaptive abilities. J Clin Psychol (1992) 0.82
Parkin-proven disease: common founders but divergent phenotypes. Neurology (2003) 0.77
Complement factor H variant increases the risk of age-related macular degeneration. Science (2005) 17.95
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
De novo mutations in epileptic encephalopathies. Nature (2013) 7.42
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Ethical, legal, and social dimensions of epilepsy genetics. Epilepsia (2006) 5.95
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet (2011) 5.01
Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol (2003) 5.00
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 4.97
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron (2013) 4.67
Impact of prenatal chlorpyrifos exposure on neurodevelopment in the first 3 years of life among inner-city children. Pediatrics (2006) 4.59
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet (2010) 4.26
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med (2012) 4.22
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet (2012) 3.80
Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet (2002) 3.73
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology (2013) 3.61
Prenatal insecticide exposures and birth weight and length among an urban minority cohort. Environ Health Perspect (2004) 3.47
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol (2008) 3.39
Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet (2008) 3.27
Contemporary-use pesticides in personal air samples during pregnancy and blood samples at delivery among urban minority mothers and newborns. Environ Health Perspect (2003) 3.08
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron (2013) 2.94
Solvent exposures and Parkinson disease risk in twins. Ann Neurol (2011) 2.92
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet (2006) 2.89
Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord (2005) 2.88
Essential tremor: emerging views of a common disorder. Nat Clin Pract Neurol (2006) 2.80
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Risk of incident dementia in essential tremor: a population-based study. Mov Disord (2007) 2.73
Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol (2008) 2.73
Clinical update: diagnosis and treatment of essential tremor. Lancet (2007) 2.66
Diagnosis and management of pergolide-induced fibrosis. Mov Disord (2004) 2.63
Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol (2007) 2.53
Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. Am J Psychiatry (2002) 2.52
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain (2013) 2.40
Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol (2005) 2.39
Elderly-onset essential tremor is associated with dementia. Neurology (2006) 2.39
Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett (2004) 2.36
Cognitive decline and literacy among ethnically diverse elders. J Geriatr Psychiatry Neurol (2005) 2.33
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet (2011) 2.28
Prevalence of essential tremor in a multiethnic, community-based study in northern Manhattan, New York, N.Y. Neuroepidemiology (2009) 2.28
Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord (2006) 2.26
Neuropsychiatric symptoms in Parkinson's disease. Mov Disord (2009) 2.20
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
Genetic testing preferences in families containing multiple individuals with epilepsy. Epilepsia (2014) 2.15
Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. Arch Neurol (2003) 2.08
Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol (2009) 2.06
Common misdiagnosis of a common neurological disorder: how are we misdiagnosing essential tremor? Arch Neurol (2006) 2.05
Doctors vs. doctors. Med Health R I (2004) 2.02
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol (2011) 2.01
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord (2013) 2.01
Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. Am J Hum Genet (2006) 2.00
Reduced Purkinje cell number in essential tremor: a postmortem study. Arch Neurol (2008) 1.99
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord (2013) 1.94